Dermira Stock Price, News & Analysis (NASDAQ:DERM)

$26.63 -0.88 (-3.20 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$27.51
Today's Range$26.46 - $28.00
52-Week Range$21.35 - $38.75
Volume336,900 shs
Average Volume427,927 shs
Market Capitalization$1.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.8

About Dermira (NASDAQ:DERM)

Dermira logoDermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

Receive DERM News and Ratings via Email

Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DERM
CUSIPN/A
Phone650-421-7200

Debt

Debt-to-Equity Ratio1.40%
Current Ratio4.68%
Quick Ratio4.68%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.58 million
Price / Sales49.14
Cash FlowN/A
Price / CashN/A
Book Value$6.95 per share
Price / Book3.83

Profitability

Trailing EPS($6.23)
Net Income$-89,080,000.00
Net Margins-992.18%
Return on Equity-41.22%
Return on Assets-23.45%

Miscellaneous

Employees95
Outstanding Shares41,670,000

Dermira (NASDAQ:DERM) Frequently Asked Questions

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

How were Dermira's earnings last quarter?

Dermira Inc (NASDAQ:DERM) released its quarterly earnings data on Monday, August, 7th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.04. The biopharmaceutical company had revenue of $1.07 million for the quarter, compared to analysts' expectations of $1 million. Dermira had a negative return on equity of 41.22% and a negative net margin of 992.18%. View Dermira's Earnings History.

Where is Dermira's stock going? Where will Dermira's stock price be in 2017?

9 brokers have issued 1 year target prices for Dermira's shares. Their forecasts range from $39.00 to $48.00. On average, they anticipate Dermira's share price to reach $42.67 in the next year. View Analyst Ratings for Dermira.

What are Wall Street analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:

  • 1. Mizuho analysts commented, "We are maintaining our Outperform rating on Bellicum. At the 2017 American Society of Hematology (ASH) meeting, the company reported immune reconstitution data from the BP-004 study of BPX-501 in pediatric patients with hematological (malignant or non-malignant) disorders, following αβ T cell depleted haploidentical HSCT (αβ Haplo-HSCT). The results highlight a robust and fast adaptive immune recovery due to the expansion and persistence of BPX-501 cells. Additionally, the company presented preclinical data of its cell therapy franchise based on a controllable switch technology, showcasing an engineered MyD88/CD40 CD19 CAR T cell with a better safety and enhanced anti-tumor activity. With BPX-501 set to drive both near-term and long-term value, the advancement of the CAR T/TCR franchise through clinical development, and a cash position of approximately $106 million (pro forma), we continue to recommend shares of Bellicum to long-term, risk-tolerant investors." (12/12/2017)
  • 2. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (11/9/2017)
  • 3. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) DERM and UCB (Not Covered) today announced that the companies have agreed to end their development and commercialization agreement for Cimzia in psoriasis so that DERM can focus on the potential launch of DRM04, which is expected in 2H18; we believe that this was the right move for DERM and did not think the Street attributed much value to Cimzia. 2) During the quarter, DERM announced a licensing agreement with Roche (Not Covered) and Genentech (Not Covered) to obtain worldwide rights to Lebrikizumab, a monoclonal antibody targeting interleukin (IL-13), for atopic dermatitis and other indications; we think this opportunity is underappreciated. 3) DERM presented glycopyrronium tosylate (formerly DRM04) data at the 26th European Academy of Dermatology and Venereology (EADV) Congress from September 13-17. 4) DERM announced that the DRM04 filing has been accepted by the FDA, with a PDUFA date of 6/30/18. 5) DERM completed patient enrollment in two DRM01 Phase 3 trials for the treatment of acne vulgaris. Finally, 6) DERM ended the quarter with $662.9MM in cash and equivalents, which should fund operations through 1H19." (11/6/2017)
  • 4. Guggenheim analysts commented, "4Q16 results underscore that DERM continues to advance its pipeline of drugs that address large unmet needs in dermatology. Positive clinical data for DRM01 and DRM04 as well as solid execution in 4Q16, give us greater conviction in our positive investment thesis for the stock. We continue to think stock price appreciation will be driven by upward consensus earnings revisions to DERM's pipeline drug sales. We also view DERM as an attractive company in a consolidating industry." (3/2/2017)

Who are some of Dermira's key competitors?

Who are Dermira's key executives?

Dermira's management team includes the folowing people:

  • Thomas G. Wiggans, Chairman of the Board, Chief Executive Officer, Co-Founder (Age 65)
  • Christopher M. Griffith, Senior Vice President - Corporate Development and Strategy, Founder (Age 40)
  • Luis C. Pena, Co-Founder, Chief Development Officer (Age 54)
  • Andrew L. Guggenhime, Chief Financial Officer, Chief Operating Officer (Age 48)
  • Lori Lyons-Williams, Chief Commercial Officer (Age 40)
  • Eugene A. Bauer M.D., Founder, Chief Medical Officer, Director (Age 74)
  • Frederick B. Craves Ph.D., Lead Independent Director (Age 70)
  • David E. Cohen M.D., Independent Director (Age 52)
  • Matthew K. Fust, Independent Director (Age 52)
  • Mark D. McDade, Independent Director (Age 61)

Who owns Dermira stock?

Dermira's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (6.35%), TimesSquare Capital Management LLC (5.47%), Eagle Asset Management Inc. (3.10%), Point72 Asset Management L.P. (1.71%), Alyeska Investment Group L.P. (0.84%) and Jana Partners LLC (0.80%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Luis C Pena, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.

Who sold Dermira stock? Who is selling Dermira stock?

Dermira's stock was sold by a variety of institutional investors in the last quarter, including Jana Partners LLC, TimesSquare Capital Management LLC, Eagle Asset Management Inc., Iguana Healthcare Management LLC, Sei Investments Co., Nationwide Fund Advisors, JPMorgan Chase & Co. and California State Teachers Retirement System. Company insiders that have sold Dermira company stock in the last year include Christopher M Griffith, David E Cohen, Eugene A Bauer, Thomas G Wiggans and William R Ringo. View Insider Buying and Selling for Dermira.

Who bought Dermira stock? Who is buying Dermira stock?

Dermira's stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Dimensional Fund Advisors LP, Ameriprise Financial Inc., AXA, Pictet Asset Management Ltd., Platinum Investment Management Ltd., C WorldWide Group Holding A S and Nicholas Investment Partners LP. View Insider Buying and Selling for Dermira.

How do I buy Dermira stock?

Shares of Dermira can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dermira's stock price today?

One share of Dermira stock can currently be purchased for approximately $26.63.

How big of a company is Dermira?

Dermira has a market capitalization of $1.13 billion and generates $22.58 million in revenue each year. The biopharmaceutical company earns $-89,080,000.00 in net income (profit) each year or ($6.23) on an earnings per share basis. Dermira employs 95 workers across the globe.

How can I contact Dermira?

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]


MarketBeat Community Rating for Dermira (DERM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dermira (NASDAQ:DERM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.402.402.25
Ratings Breakdown: 3 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $42.67$43.71$44.38$43.17
Price Target Upside: 60.82% upside51.21% upside74.50% upside56.86% upside

Dermira (NASDAQ:DERM) Consensus Price Target History

Price Target History for Dermira (NASDAQ:DERM)

Dermira (NASDAQ:DERM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017MizuhoLower Price TargetBuy$43.00 -> $39.00MediumView Rating Details
12/5/2017GuggenheimInitiated CoverageBuy -> BuyMediumView Rating Details
11/29/2017Cantor FitzgeraldSet Price TargetBuy$45.00HighView Rating Details
11/7/2017Leerink SwannReiterated RatingOutperform$47.00 -> $41.00N/AView Rating Details
11/7/2017Needham & Company LLCReiterated RatingBuy -> Buy$46.00 -> $43.00N/AView Rating Details
6/29/2017Evercore ISIInitiated CoverageOutperform$48.00MediumView Rating Details
3/16/2017Raymond James FinancialInitiated CoverageUnderperform -> UnderperformHighView Rating Details
3/15/2017CitigroupInitiated CoverageUnderperformHighView Rating Details
1/3/2017SEB Equity ResearchReiterated RatingReduceN/AView Rating Details
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Dermira (NASDAQ:DERM) Earnings History and Estimates Chart

Earnings by Quarter for Dermira (NASDAQ:DERM)

Dermira (NASDAQ DERM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.89)($0.93)$1.00 million$1.07 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.93)($0.21)$22.47 millionViewListenView Earnings Details
11/7/2016Q316($0.72)($0.72)$0.12 millionViewN/AView Earnings Details
8/8/2016Q2($0.86)($0.89)ViewN/AView Earnings Details
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details
11/10/2015Q3($0.77)($0.58)$7.30 millionViewN/AView Earnings Details
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details
3/25/2015Q4($0.59)($0.29)$7.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Dermira (NASDAQ:DERM) Earnings Estimates

2017 EPS Consensus Estimate: ($3.99)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.84)($0.84)($0.84)
Q2 20171($0.81)($0.81)($0.81)
Q3 20171($1.03)($1.03)($1.03)
Q4 20171($1.31)($1.31)($1.31)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dermira (NASDAQ:DERM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Dermira (NASDAQ DERM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 99.54%
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Dermira (NASDAQ DERM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017David E CohenDirectorSell600$25.49$15,294.00View SEC Filing  
11/2/2017Thomas G. WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
11/1/2017David E CohenDirectorSell600$26.82$16,092.00View SEC Filing  
10/11/2017Eugene A BauerInsiderSell7,500$30.04$225,300.00View SEC Filing  
10/10/2017Thomas G WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
10/2/2017David E CohenDirectorSell600$26.99$16,194.00View SEC Filing  
9/18/2017Thomas G. WiggansCEOSell9,500$27.51$261,345.00View SEC Filing  
9/1/2017David E CohenDirectorSell600$23.56$14,136.00View SEC Filing  
8/28/2017David E CohenDirectorSell600$23.81$14,286.00View SEC Filing  
8/14/2017Fred B CravesDirectorBuy30,000$23.03$690,900.00View SEC Filing  
8/1/2017Thomas G. WiggansCEOSell500$27.58$13,790.00View SEC Filing  
7/5/2017Eugene A BauerInsiderSell2,500$30.00$75,000.00View SEC Filing  
7/3/2017Thomas G. WiggansCEOSell5,000$29.06$145,300.00View SEC Filing  
6/20/2017Eugene A BauerInsiderSell2,500$30.01$75,025.00View SEC Filing  
6/2/2017Thomas G. WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
5/15/2017Christopher M. GriffithSVPSell1,312$27.07$35,515.84View SEC Filing  
4/17/2017Christopher M. GriffithSVPSell1,303$33.97$44,262.91View SEC Filing  
4/3/2017Eugene A BauerInsiderSell2,500$33.53$83,825.00View SEC Filing  
4/3/2017Thomas G WiggansCEOSell8,000$33.49$267,920.00View SEC Filing  
4/3/2017William R RingoDirectorSell500$34.03$17,015.00View SEC Filing  
3/15/2017Christopher M. GriffithSVPSell1,303$35.79$46,634.37View SEC Filing  
3/1/2017Eugene A BauerInsiderSell2,500$33.61$84,025.00View SEC Filing  
3/1/2017Thomas G WiggansCEOSell11,000$33.54$368,940.00View SEC Filing  
3/1/2017William R RingoDirectorSell500$35.09$17,545.00View SEC Filing  
2/15/2017Christopher M. GriffithSVPSell1,303$30.79$40,119.37View SEC Filing  
2/15/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
2/14/2017Eugene A BauerInsiderSell1,505$30.00$45,150.00View SEC Filing  
2/1/2017Eugene A BauerInsiderSell995$30.00$29,850.00View SEC Filing  
1/17/2017Christopher M. GriffithVPSell1,303$29.11$37,930.33View SEC Filing  
1/4/2017Thomas G WiggansCEOSell8,000$31.06$248,480.00View SEC Filing  
1/4/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
1/3/2017Eugene A BauerInsiderSell2,500$30.07$75,175.00View SEC Filing  
12/16/2016William R RingoDirectorSell125$32.00$4,000.00View SEC Filing  
12/15/2016Christopher M. GriffithVPSell1,303$30.70$40,002.10View SEC Filing  
12/14/2016Eugene A BauerInsiderSell2,500$30.36$75,900.00View SEC Filing  
12/1/2016Thomas G WiggansCEOSell11,000$30.80$338,800.00View SEC Filing  
12/1/2016William R RingoDirectorSell375$32.00$12,000.00View SEC Filing  
11/9/2016Andrew GuggenhimeCFOSell4,100$35.02$143,582.00View SEC Filing  
11/9/2016William R RingoDirectorSell500$32.30$16,150.00View SEC Filing  
11/1/2016Thomas G WiggansCEOSell11,000$31.19$343,090.00View SEC Filing  
10/17/2016Christopher M GriffithVPSell1,303$32.33$42,125.99View SEC Filing  
10/11/2016Andrew GuggenhimeCFOSell10,900$34.34$374,306.00View SEC Filing  
10/3/2016Thomas G WiggansCEOSell11,000$34.60$380,600.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$34.25$17,125.00View SEC Filing  
9/19/2016Andrew GuggenhimeCFOSell15,000$35.01$525,150.00View SEC Filing  
9/15/2016Christopher M GriffithVPSell1,303$33.26$43,337.78View SEC Filing  
9/12/2016Andrew GuggenhimeCFOSell10,000$32.53$325,300.00View SEC Filing  
9/1/2016Thomas G WiggansCEOSell11,000$31.63$347,930.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
8/15/2016Christopher M GriffithVPSell1,303$31.75$41,370.25View SEC Filing  
8/11/2016Andrew GuggenhimeCFOSell10,000$31.02$310,200.00View SEC Filing  
8/1/2016Eugene A BauerInsiderSell2,500$33.18$82,950.00View SEC Filing  
8/1/2016Thomas G WiggansCEOSell11,000$33.19$365,090.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$33.65$16,825.00View SEC Filing  
7/15/2016Christopher M GriffithVPSell1,303$30.02$39,116.06View SEC Filing  
7/11/2016Andrew GuggenhimeCFOSell10,000$30.15$301,500.00View SEC Filing  
7/5/2016Thomas G WiggansCEOSell11,000$29.62$325,820.00View SEC Filing  
7/1/2016Eugene A BauerInsiderSell2,500$29.48$73,700.00View SEC Filing  
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.00View SEC Filing  
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.00View SEC Filing  
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.80View SEC Filing  
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dermira (NASDAQ DERM) News Headlines

Source:
DateHeadline
Dermira Inc (DERM) Given Average Recommendation of "Hold" by BrokeragesDermira Inc (DERM) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 14 at 10:10 AM
Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : December 12, 2017Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : December 12, 2017
finance.yahoo.com - December 12 at 10:07 AM
Dermira (DERM) Earns Buy Rating from Analysts at GuggenheimDermira (DERM) Earns Buy Rating from Analysts at Guggenheim
www.americanbankingnews.com - December 5 at 9:30 PM
Insider Selling: Dermira Inc (DERM) Director Sells 600 Shares of StockInsider Selling: Dermira Inc (DERM) Director Sells 600 Shares of Stock
www.americanbankingnews.com - December 5 at 8:00 PM
Dermira (DERM) Upgraded by BidaskClub to "Hold"Dermira (DERM) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - December 2 at 2:40 PM
Contrasting Dermira (DERM) & Vascular Biogenics (VBLT)Contrasting Dermira (DERM) & Vascular Biogenics (VBLT)
www.americanbankingnews.com - December 2 at 3:28 AM
Cantor Fitzgerald Analysts Give Dermira (DERM) a $45.00 Price TargetCantor Fitzgerald Analysts Give Dermira (DERM) a $45.00 Price Target
www.americanbankingnews.com - November 30 at 12:00 PM
Dermira Inc (DERM): What Are The Future Prospects?Dermira Inc (DERM): What Are The Future Prospects?
finance.yahoo.com - November 28 at 5:10 PM
Dermira, Inc. (DERM) Receives Consensus Rating of "Hold" from AnalystsDermira, Inc. (DERM) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 19 at 9:50 AM
Dermira, Inc. – Value Analysis (NASDAQ:DERM) : November 10, 2017Dermira, Inc. – Value Analysis (NASDAQ:DERM) : November 10, 2017
finance.yahoo.com - November 10 at 5:49 PM
Cantor Fitzgerald Weighs in on Dermira, Inc.s FY2018 Earnings (DERM)Cantor Fitzgerald Weighs in on Dermira, Inc.'s FY2018 Earnings (DERM)
www.americanbankingnews.com - November 10 at 5:40 PM
Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : November 9, 2017Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : November 9, 2017
finance.yahoo.com - November 10 at 9:30 AM
Dermira to Present at Upcoming Investor Conferences in NovemberDermira to Present at Upcoming Investor Conferences in November
feeds.benzinga.com - November 9 at 6:52 PM
Brokers Set Expectations for Dermira, Inc.s Q4 2017 Earnings (DERM)Brokers Set Expectations for Dermira, Inc.'s Q4 2017 Earnings (DERM)
www.americanbankingnews.com - November 9 at 9:58 AM
Dermira (DERM), UCB Agree to End Collaboration Agreement for CIMZIADermira (DERM), UCB Agree to End Collaboration Agreement for CIMZIA
www.streetinsider.com - November 9 at 12:44 AM
$1.10 Million in Sales Expected for Dermira, Inc. (DERM) This Quarter$1.10 Million in Sales Expected for Dermira, Inc. (DERM) This Quarter
www.americanbankingnews.com - November 8 at 6:32 AM
Dermira, Inc. (DERM) Earns Buy Rating from Cantor FitzgeraldDermira, Inc. (DERM) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - November 7 at 12:16 AM
BRIEF-Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylateBRIEF-Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate
www.reuters.com - November 7 at 12:16 AM
Why this Peninsula drug maker isnt sweating it, even after a couple of big dealsWhy this Peninsula drug maker isn't sweating it, even after a couple of big deals
www.bizjournals.com - November 7 at 12:16 AM
Dermira and UCB Agree to End Collaboration Agreement for CIMZIADermira and UCB Agree to End Collaboration Agreement for CIMZIA
finance.yahoo.com - November 6 at 7:14 PM
Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary HyperhidrosisDermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis
finance.yahoo.com - November 6 at 7:14 PM
Dermira reports 3Q lossDermira reports 3Q loss
finance.yahoo.com - November 6 at 7:14 PM
Dermira, Inc. (DERM) Expected to Post Earnings of -$1.12 Per ShareDermira, Inc. (DERM) Expected to Post Earnings of -$1.12 Per Share
www.americanbankingnews.com - November 6 at 3:08 PM
Dermira, Inc. (DERM) Director Sells $16,092.00 in StockDermira, Inc. (DERM) Director Sells $16,092.00 in Stock
www.americanbankingnews.com - November 3 at 9:44 PM
Dermira, Inc. (DERM) CEO Sells $137,600.00 in StockDermira, Inc. (DERM) CEO Sells $137,600.00 in Stock
www.americanbankingnews.com - November 3 at 9:24 PM
Comparing Dermira (DERM) & Its RivalsComparing Dermira (DERM) & Its Rivals
www.americanbankingnews.com - November 2 at 1:28 AM
Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : October 27, 2017Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : October 27, 2017
finance.yahoo.com - October 28 at 1:16 AM
Dermira, Inc. (DERM) Receives Consensus Recommendation of "Hold" from AnalystsDermira, Inc. (DERM) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 25 at 2:55 PM
 Brokerages Expect Dermira, Inc. (DERM) Will Announce Quarterly Sales of $1.05 Million Brokerages Expect Dermira, Inc. (DERM) Will Announce Quarterly Sales of $1.05 Million
www.americanbankingnews.com - October 19 at 4:48 AM
 Analysts Anticipate Dermira, Inc. (DERM) to Post -$1.12 EPS Analysts Anticipate Dermira, Inc. (DERM) to Post -$1.12 EPS
www.americanbankingnews.com - October 17 at 8:24 PM
Corporate News Blog - Dermira Highlights Results from ARIDO Study for Assessment of Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis PatientsCorporate News Blog - Dermira Highlights Results from ARIDO Study for Assessment of Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis Patients
finance.yahoo.com - October 16 at 6:34 PM
Dermira (DERM) Announces New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary HyperhidrosisDermira (DERM) Announces New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis
www.streetinsider.com - October 14 at 5:39 PM
Dermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology ConferenceDermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference
finance.yahoo.com - October 13 at 6:22 PM
Eugene A. Bauer Sells 7,500 Shares of Dermira, Inc. (DERM) StockEugene A. Bauer Sells 7,500 Shares of Dermira, Inc. (DERM) Stock
www.americanbankingnews.com - October 13 at 1:34 PM
Insider Selling: Dermira, Inc. (DERM) CEO Sells 5,000 Shares of StockInsider Selling: Dermira, Inc. (DERM) CEO Sells 5,000 Shares of Stock
www.americanbankingnews.com - October 11 at 10:34 PM
Dermira (DERM) Shares Cross Above 200 DMADermira (DERM) Shares Cross Above 200 DMA
www.nasdaq.com - October 11 at 7:21 PM
Dermira, Inc. (DERM) Soars: Stock Adds 5.3% in SessionDermira, Inc. (DERM) Soars: Stock Adds 5.3% in Session
finance.yahoo.com - October 11 at 7:21 PM
Surprising Analyst 12-Month Target For IHESurprising Analyst 12-Month Target For IHE
www.nasdaq.com - October 9 at 6:13 PM
Dermira Completes Patient Enrollment in Two Phase 3 Pivotal Trials of Olumacostat Glasaretil for the Treatment of Acne VulgarisDermira Completes Patient Enrollment in Two Phase 3 Pivotal Trials of Olumacostat Glasaretil for the Treatment of Acne Vulgaris
finance.yahoo.com - October 5 at 10:29 AM
David E. Cohen Sells 600 Shares of Dermira, Inc. (DERM) StockDavid E. Cohen Sells 600 Shares of Dermira, Inc. (DERM) Stock
www.americanbankingnews.com - October 3 at 11:56 PM
Dermira, Inc. (DERM) Expected to Announce Quarterly Sales of $1.05 MillionDermira, Inc. (DERM) Expected to Announce Quarterly Sales of $1.05 Million
www.americanbankingnews.com - October 1 at 1:02 PM
Dermira, Inc. (DERM) Given Consensus Rating of "Hold" by AnalystsDermira, Inc. (DERM) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - September 30 at 1:04 PM
-$1.12 EPS Expected for Dermira, Inc. (DERM) This Quarter-$1.12 EPS Expected for Dermira, Inc. (DERM) This Quarter
www.americanbankingnews.com - September 29 at 4:28 AM
Cantor Fitzgerald Reaffirms "Buy" Rating for Dermira, Inc. (DERM)Cantor Fitzgerald Reaffirms "Buy" Rating for Dermira, Inc. (DERM)
www.americanbankingnews.com - September 27 at 6:10 PM
Commit To Buy Dermira At $17.50, Earn 29.6% Annualized Using OptionsCommit To Buy Dermira At $17.50, Earn 29.6% Annualized Using Options
www.nasdaq.com - September 22 at 10:14 PM
Dermira to Present at Cantor Fitzgerald Global Healthcare ConferenceDermira to Present at Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 6:39 PM
Thomas G. Wiggans Sells 9,500 Shares of Dermira, Inc. (DERM) StockThomas G. Wiggans Sells 9,500 Shares of Dermira, Inc. (DERM) Stock
www.americanbankingnews.com - September 19 at 7:42 PM
Dermira, Inc. – Value Analysis (NASDAQ:DERM) : September 19, 2017Dermira, Inc. – Value Analysis (NASDAQ:DERM) : September 19, 2017
finance.yahoo.com - September 18 at 10:51 PM
Dermira, Inc. (DERM) Stock Rating Reaffirmed by Needham & Company LLCDermira, Inc. (DERM) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:58 AM
Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : September 15, 2017Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : September 15, 2017
finance.yahoo.com - September 15 at 6:20 PM

SEC Filings

Dermira (NASDAQ:DERM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dermira (NASDAQ:DERM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dermira (NASDAQ DERM) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.